Daily Roundup| Celcuity Revtorpyk Approved: The Label Line That Makes It a Takeout Target

Daily Roundup| GSK Kills Camlipixant: The $2B Bellus Bet Unravels

GSK shelved camlipixant after mixed Phase 3 data — the thirdP2X3 chronic cough drug to fail and a blow to its ~$2B Bellus Health deal. Plus Jasper Therapeutics' lifeline merger with Kira and a $132M raise, Novartis Fabhalta's full FDA approval in IgA nephropathy, Lilly's $2.8B AtaiBeckley psychedelics buyout, a Merck ADC lung cancer readout, and a Pfizer downgrade. Visit us at www.thepharmacloseout.comTagspharma, biotech, FDA, clinical trials, drug approvals,camlipixant, GSK, Bellus Health, Jasper Therapeutics, Novartis Fabhalta, IgA nephropathy, chronic cough

Daily Roundup| Merck's Sac-TMT Beats Chemo in Lung Cancer — Keytruda's Cliff Answer Merck's Sac-TMT Beats Chemo in

Merck's sac-TMT beat chemotherapy in first-line PD-L1-negative lung cancer — the emerging answer to Keytruda's patent cliff. Plus: Europe approves Novo Nordisk's oral Wegovy ahead of Eli Lilly, Sanofi sues Pfizer and Moderna over mRNA patents, Bora and Insilico Medicine ink a $2.5B AI alliance, the FDA resumes publishing complete response letters, Q32 Bio surges on alopecia areata data, and Veradermics posts a Phase 2 win in female pattern hair loss. Visit us at www.thepharmacloseout.com Tagspharma, biotech, FDA, clinical trials, drug approvals,sac-TMT, Merck, Kelun-Biotech, oral Wegovy, Novo Nordisk, NSCLC, obesity

Daily Roundup| Celcuity Revtorpyk Approved: The Label Line That Makes It a Takeout Target

Celcuity's Revtorpyk (gedatolisib) wins FDA approval in HR+/HER2- breast cancer on a 0.24 hazard ratio — and the stock jumped to $111. Plus AstraZeneca's up-to-$1.5B Zegfrovy license from spinoff Dizal, Biogen's diranersen tau data at AAIC, the NextCure–Avere oral IL-23 merger, and Roche scrapping two Ionis Huntington's programs. Visit us at www.thepharmacloseout.com Tags pharma, biotech, FDA, clinical trials, drug approvals, Celcuity, gedatolisib Revtorpyk, HR+ breast cancer, AstraZeneca Dizal Zegfrovy, Biogen diranersen tau, NextCure Avere IL-23, PIK3CA

Daily Roundup| GSK to File Jemperli in Rectal Cancer After Phase 2 Win

GSK will file Jemperli with the FDA for dMMR rectal cancer after a Phase 2 win, extending its PD-1 franchise into curative-intent oncology. Plus Q32 Bio's bempikibart hits its alopecia areata goal, the FDA finalizes psychedelics guidance ahead of a Compass Pathways COMP360 decision, LEQEMBI clears a subcutaneous at-home dose for Eisai and Biogen, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, and Biogen's tau drug diranersen takes the spotlight at AAIC. Visit us at www.thepharmcloseout.com Tags pharma, biotech, FDA, clinical trials, drug approvals, Jemperli, GSK, Q32 Bio, alopecia areata, Compass Pathways, LEQEMBI, rectal cancer

Last Week's Recap| AstraZeneca's Wainua Stumbles: The Week the Clinic Pushed Back on Pharma's Deal Boom

AstraZeneca's Wainua missed in cardiomyopathy — one of three clinical setbacks in five days even as pharma dealmaking stayed red-hot with Vertex's ~$10B Crinetics buy and GSK's biggest oncology bet in a decade. Webreak down what the Wainua miss means for the ATTR cardiomyopathy race, Bausch + Lomb's BL1107 glaucoma flop, the third Hengrui/Elevar liver-cancer rejection, Corcept's misread insider sale and late-2026 Cushing's catalyst forrelacorilant, plus the week ahead: Q32 Bio's bempikibart in alopecia areata, Celcuity's gedatolisib FDA decision in breast cancer, Novartis's pelacarsen, and Lilly's muted Foundayo launch. Visit us at www.thepharmacloseout.com Tagspharma, biotech, FDA, clinical trials, drug approvals,Wainua, AstraZeneca, ATTR cardiomyopathy, Corcept Therapeutics, gedatolisib, Q32 Bio, alopecia areata